Center for Professional Development

The Evidence for HPV Self-Sampling: A Clinician's Guide

Course ID: EHPV
2.5 Contact Hours

Offered Online

 

Register for The Evidence for HPV Self-Sampling »


Registration

 

Description

Though endorsed by the American Society for Colposcopy and Cervical Pathology (ASCCP) and the Society of Gynecologic Oncologists (SGO) in 2015, primary hrHPV testing for cervical cancer screening is not routinely practiced within the United States. Primary hrHPV self-sampling affords women the opportunity to bypass the traditional pelvic exam and Pap test, however, at present, there are no FDA approved cervicovaginal cell self-collection devices for hrHPV testing in the U.S. Furthermore, there is confusion regarding the multiplicity of cervical cancer screening guidelines, and the specific recommendations for women living with HIV.

The purpose of this course is to serve as a review for clinicians on the role of HPV in cervical cancer, current guidelines for screening and special considerations for HIV-positive women, as well as to provide information about primary HPV testing and hrHPV self-sampling and analyze intent to offer hrHPV self-sampling to patients, if FDA approved. It is hoped that documentation of clinician support would provide support for FDA review of these devices in the future.

Objectives

 

Questions?

cpdn@rutgers.edu
973-972-6655

ˆ Back to Top | View more continuing education courses »

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

View all courses by date

 

© 2018 Rutgers, The State University of New Jersey. All rights reserved.
DonateJoin Our Mailing ListEmployment OpportunitiesWebsite Feedback